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Summary
Background The ALLR3 trial investigated outcomes of children with B-cell precursor acute lymphoblastic leukaemia 
who had late bone marrow relapses. We analysed long-term follow-up outcomes of these patients.
Methods ALLR3 was an open-label randomised clinical trial that recruited children aged 1–18 years with B-cell precursor 
acute lymphoblastic leukaemia who had late bone marrow relapses. Eligible patients were recruited from centres in 
Australia, Ireland, the Netherlands, New Zealand, and the UK. Patients were randomly assigned from Jan 31, 2003, to 
Dec 31, 2007, and the trial closed to recruitment on Oct 31, 2013. Randomly assigned patients were allocated to receive 
either idarubicin or mitoxantrone in induction by stratified concealed randomisation; after randomisation stopped in 
Dec 31, 2007, all patients were allocated to receive mitoxantrone. After three blocks of therapy, patients with high minimal 
residual disease (≥10–⁴ cells) at the end of induction were allocated to undergo allogeneic stem-cell transplantation and 
those with low minimal residual disease (<10–⁴ cells) at the end of induction were allocated to receive chemotherapy. 
Minimal residual disease level was measured by real-time quantitative PCR analysis of immunoglobulin and T-cell 
receptor gene rearrangements. The primary endpoint of the original ALLR3 clinical trial was progression-free survival of 
randomly assigned patients. The primary endpoint of this long-term follow-up analysis was progression-free survival of 
patients with late bone marrow relapses stratified by minimal residual disease level. Outcomes were correlated with age, 
site, time to recurrence, and genetic subtypes, and analysed by both intention to treat and actual treatment received. This 
trial is registered on the ISRCTN registry, number ISRCTN45724312, and on ClinicalTrials.gov, number NCT00967057.
Findings Between Feb 2, 2003, and Oct 28, 2013, 228 patients with B-cell precursor acute lymphoblastic leukaemia and 
late bone marrow relapses were treated. After a median follow-up of 84 months (IQR 48–109), progression-free 
survival of all randomly assigned patients was 60% (95% CI 54–70). 220 patients achieved second complete remission, 
and minimal residual disease was evaluable in 192 (87%). 110 patients with late bone marrow relapses and high 
minimal residual disease at the end of induction were allocated to undergo stem-cell transplantation, and 82 patients 
with low minimal residual disease at the end of induction were allocated to receive chemotherapy. In the patients 
allocated to undergo stem-cell transplantation, four relapses and three deaths were reported before the procedure, 
and 11 patients were not transplanted. Of the 92 patients transplanted, 58 (63%) remained in second complete 
remission, 13 (14%) died of complications, and 21 (23%) relapsed after stem-cell transplantation. In patients allocated 
to receive chemotherapy, one early treatment-related death was reported and 11 patients were transplanted. Of the 
70 patients who continued on chemotherapy, 49 (70%) remained in second complete remission, two (3%) died of 
complications, and 19 (27%) relapsed. Progression-free survival at 5 years was 56% (95% CI 46–65) in those with high 
minimal residual disease and 72% (60–81) in patients with low minimal residual disease (p=0·0078). Treatment-
related serious adverse events were not analysed in the long-term follow-up.
Interpretation Patients with B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses and low 
minimal residual disease at end of induction had favourable outcomes with chemotherapy without undergoing stem-
cell transplantation. Patients with high minimal residual disease benefited from stem-cell transplantation, and 
targeted therapies might offer further improvements in outcomes for these patients.
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Introduction
Outcomes after isolated or combined bone marrow 
relapses in patients with childhood B-cell precursor acute 
lymphoblastic leukaemia are associated with the duration 
of first complete remission. Irrespective of treatment 
strategies, children relapsing more than 6 months after 
stopping therapy have better survival rates than those who 
relapse earlier (overall survival 45–73% for those who 
relapse >6 months later vs 22–38% for those who relapse 
earlier),1–4 suggesting that recurring blasts remain 
chemosensitive in many patients. The BFM Study Group 
identified a subset of patients with late bone marrow 
relapses (isolated or combined) who had low minimal 
residual disease (defined as <10–³ cells) at end of induction 
and could thus be maintained in second complete 
remission with chemotherapy and targeted radiotherapy.5 
Those with minimal residual disease comprising 10–³ cells 
or more, however, frequently had a second relapse. The 
Children’s Oncology Group (USA), in a smaller cohort of 
patients, showed substantially better outcomes in patients 
with end-of-induction minimal residual disease 
comprising fewer than 10–⁴ cells than in those with 
minimal residual disease comprising 10–⁴ cells or more.6 
Consequently, the ALLREZ BFM 2002 clinical trial 
Research in context
Evidence before the study
We searched for articles published in PubMed before 
September, 2018, without date limitations, for outcomes of 
children with “B-cell precursor acute lymphoblastic leukaemia” 
and “bone marrow relapse”; the search was further refined to 
include only those patients with a relapse 36 months after the 
first diagnosis or more than 6 months after stopping front-line 
therapy and who were treated uniformly for relapse, 
with minimal residual disease measured after induction. 
Two relevant studies were identified. The Children’s Oncology 
Group ALL 01P2 study treated 55 patients with B-cell precursor 
acute lymphoblastic leukaemia and late bone marrow relapses. 
1-year event-free survival was 86% (SD 8) in patients with 
end-of-induction minimal residual disease comprising fewer 
than 10–⁴ cells and was 77% (SD 9; p=0·005) for those with 
minimal residual disease comprising 10–⁴ cells or more. Details 
of allogeneic stem-cell transplantation were not available. The 
BFM REZ 2002 study treated 236 patients with B-cell precursor 
acute lymphoblastic leukaemia and late bone marrow relapses. 
8-year event-free survival was 70% (SD 5) for patients with 
end-of-induction minimal residual disease comprising fewer 
than 10–³ cells stratified for no stem-cell transplantation, and 
64% (SD 5; p=0·29) in those with end-of-induction minimal 
residual disease comprising 10–³ cells or more, stratified for 
stem-cell transplantation. We next searched for studies 
describing outcomes of children with relapsed B-cell precursor 
acute lymphoblastic leukaemia in whom minimal residual 
disease assessment was done before stem-cell transplantation. 
We identified six articles. Five were retrospective, not stratified 
by the time to relapse, and identified a pre-stem-cell 
transplantation minimal residual disease of 10–⁴ cells or more as 
being predictive of relapse after stem-cell transplantation. The 
BFM REZ 96 and 2002 trials prospectively analysed minimal 
residual disease before stem-cell transplantation in 35 patients 
with B-cell precursor acute lymphoblastic leukaemia and late 
bone marrow relapses. 4-year event-free survival was 68% 
(SD 12) in patients with minimal residual disease of fewer than 
10–⁴ cells before stem-cell transplantation and 20% (SD 12; 
p=0·02) in those with minimal residual disease of 10–⁴ cells or 
more. These studies suggest that a proportion of children with 
B-cell precursor acute lymphoblastic leukaemia and late bone 
marrow relapses do not require stem-cell transplantation to 
maintain long-term remission as ascertained by end-of-
induction minimal residual disease. For those requiring a 
transplant, minimal residual disease of 10–⁴ cells or more before 
stem-cell transplantation appears to be associated with high 
recurrence rates after stem-cell transplantation.
Added value of this study
In this long-term follow-up of patients in the ALLR3 trial with 
B-cell precursor acute lymphoblastic leukaemia who had late 
bone marrow relapses, a high end-of-induction minimal 
residual disease level of 10–⁴ cells or more was used to stratify 
patients to stem-cell transplantation. Patients with low 
minimal residual disease (defined as <10–⁴ cells) had 
significantly better progression-free survival and overall 
survival than did those with high minimal residual disease, 
suggesting that this is the preferred level to ascertain eligibility 
of patients for stem-cell transplantation. High-risk cytogenetic 
groups and IKZF1, PAX5, or NR3C1 deletions or NRAS mutations 
were associated with higher levels of minimal residual disease 
and poor outcomes. Patients with high minimal residual 
disease (≥10–⁴ cells) before stem-cell transplantation had 
reasonable outcomes after stem-cell transplantation.
Implications of all available evidence
An end-of-induction minimal residual disease of fewer than 
10–⁴ cells in patients with B-cell precursor acute lymphoblastic 
leukaemia and late bone marrow relapses is associated with 
favourable outcomes with systemic chemotherapy and 
avoidance of cranial irradiation in those without CNS 
involvement. In this group, improvements in the sensitivity of 
techniques for detecting minimal residual disease might allow 
further refinement; second relapses are salvageable with 
stem-cell transplantation in patients who are in 
third complete remission, and experimental therapies will 
require careful evaluation. Although patients with 
end-of-induction minimal residual disease of 10–⁴ cells or 
more benefited from stem-cell transplantation in this study, 
transplant-related mortality and relapse rates after stem-cell 
transplantation remained problematic; this group might 
benefit from newer treatment modalities.
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assigned patients with end-of-induction minimal residual 
disease of 10–³ cells or more to allogeneic stem-cell 
transplantation, while patients with end-of-induction 
minimal residual disease comprising fewer than 10–³ cells 
were allocated to chemotherapy with cranial irradiation 
for isolated late bone marrow relapses and targeted 
radiotherapy for combined relapses.3 The international 
collaborative ALLR3 clinical trial protocol recommended 
stem-cell transplantation for patients with B-cell precursor-
acute lymphoblastic leukaemia and late bone marrow 
relapses with an end-of-induction minimal residual 
disease of 10–⁴ cells or more, whereas those with minimal 
residual disease of fewer than 10–⁴ cells were assigned to 
chemotherapy. The ALLR3 trial used a four-drug 
anthracycline-based induction, similarly to the COG trial,6 
which also used a minimal residual disease level of 
10–⁴ cells, and in contrast to the anthracycline-free 
induction in the ALLREZ BFM trial,5 which used a 
minimal residual disease level of 10–³ cells. In the ALLR3 
trial, patients were randomly assigned to receive idarubicin 
versus mitoxan trone in induction. Mitoxantrone had a 
substantial effect on progression-free survival and overall 
survival compared with idarubicin, despite similar levels 
of end-of-induction minimal residual disease in the two 
groups.7 This study did not report on the outcomes of 
minimal residual disease risk stratification.
Treatment and other biological factors affect outcomes 
of patients with relapsed acute lymphoblastic leukaemia, 
independently of end-of-induction minimal residual 
disease status; in particular, high-risk cytogenetics and 
deletions and mutations in TP53 have been shown to be 
associated with poor outcomes in patients with late bone 
marrow relapses, irrespective of minimal residual 
disease following induction.8,9 Here, we report long-term 
follow-up outcomes of the ALLR3 trial, in which patients 
with B-cell precursor acute lymphoblastic leukaemia who 
had late isolated and combined bone marrow relapses 
were stratified to continue chemotherapy or to have 
stem-cell transplantation on the basis of their end-of-
induction minimal residual disease. We also investigated 
the influence of cytogenetics, previously identified 
prognostic somatic copy number alterations,8 and re- 
current gene mutations, including the recent char-
acterisation of IKZFplus.10
Methods
Study design and participants
ALLR3 was an open-label randomised clinical trial that 
recruited children aged 1–18 years with B-cell precursor 
acute lymphoblastic leukaemia who had isolated or 
combined late bone marrow relapses. Patients were 
recruited from children’s centres in Australia, Ireland, 
the Netherlands, New Zealand, and the UK,9 and were 
randomly assigned from Jan 31, 2003, to Dec 31, 2007; 
the trial closed to recruitment on Oct 31, 2013. The study 
was approved by the relevant ethics committees in each 
country and patients were recruited after written consent 
was obtained from parents or carers. Outcomes of 
patients with late isolated extramedullary relapses have 
been previously published and are excluded from these 
analyses.11
Details of randomisation, risk stratification, and results 
of the randomised study along with the ALLR3 protocol 
have been reported previously7,8,11 and are summarised in 
the appendix (p 1). From Jan 31, 2003, to Dec 31, 2007, 
patients were randomly assigned to receive either 
mitoxantrone or idarubicin during induction. By 
Dec 31, 2007, randomisation was stopped because of 
differences in progression-free survival and overall 
survival between the two groups, with mitoxantrone 
conferring a significant benefit. After randomisation was 
stopped, patients continued to receive mitoxantrone until 
closure of the trial on Oct 31, 2013.
Late relapses were defined as those occurring more 
than 6 months after the end of front-line therapy. Isolated 
late bone marrow relapses were defined as more than 
25% blasts in the bone marrow and combined late bone 
marrow relapses defined as more than 5% bone marrow 
blasts, along with at least one extramedullary disease site. 
CNS relapse was defined as pleocytosis (>5 blasts per µL) 
with blasts in the cerebrospinal fluid (CSF). Testicular 
disease was diagnosed clinically and confirmed by biopsy 
or ultrasonography. All patients with late bone marrow 
relapses were treated with three blocks of chemotherapy. 
A four-drug induction with pulsed dexamethasone, 
anthracycline, vincristine, and polyethylene glycol 
conjugated L-asparaginase was followed by a con-
solidation block with high-dose methotrexate, cyclo-
phosphamide, and etoposide. The third inten sification 
block consisted of high-dose cytarabine followed by high-
dose methotrexate. Patients were defined as having 
achieved second complete remission when bone marrow 
blasts were less than 5% at the end of induction (with 
normal CSF findings if they had concomitant CNS 
disease). Patients were stratified to receive a matched 
donor stem-cell transplantation or chemotherapy on the 
basis of minimal residual disease levels at the end of 
induction. This was a predefined secondary outcome of 
the ALLR3 trial.
Procedures
Minimal residual disease was measured from bone 
marrow samples obtained at the end of induction 
(timepoint 1) and again either before stem-cell trans- 
plantation or at the end of block 3 chemotherapy 
(timepoint 2) by use of real-time quantitative PCR 
analysis of immunoglobulin and T-cell receptor gene 
rearrangements.7,12 At timepoint 1, high minimal residual 
disease, measured by at least one marker, was defined as 
10–⁴ cells or more, whereas low minimal residual disease, 
measured by two sensitive markers, was defined as fewer 
than 10–⁴ cells. When minimal residual disease was not 
measured or markers had lower sensitivity, these data 
were reported as being not available. Patients with 
See Online for appendix
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isolated or combined late bone marrow relapses and high 
minimal residual disease after induction were eligible for 
matched-donor stem-cell transplantation following 
completion of the third (or phase 3) chemotherapy 
treatment block. Those with low minimal residual 
disease continued with further chemotherapy alone 
(isolated late bone marrow relapses) or with site-directed 
radiotherapy (combined late bone marrow relapses). 
Where the minimal residual disease measurement was 
not available, patients with a relapse less than 24 months 
after stopping therapy were eligible for stem-cell 
transplantation.1,7 In this report, stem-cell donors 
matched at 10/10 HLA loci were classified as matched 
donors and the rest as mismatched donors, including 
mismatched unrelated and haploidentical related donors. 
Cord refers to stem-cell transplantation done with donor 
cord blood stem cells.
Cytogenetic analysis was done locally and reviewed 
centrally by the Leukaemia Research Cytogenetics Group. 
Where information about cytogenetics not available for 
relapse, cytogenetics at first presentation was used. 
Integrated cytogenetics and molecular genetics were 
used to categorise patients into standard-risk, 
intermediate-risk, and high-risk genetic groups, as 
reported previously.7 The copy number status of IKZF1, 
CDKN2A/B, PAX5, EBF1, ETV6, BTG1, RB1, NR3C1, and 
PAR1 were ascertained with the SALSA Multiplex 
Ligation dependent Probe Amplification (MLPA) kit 
P335 (MRC Holland, Amsterdam, Netherlands). TP53 
deletions were assessed by a combination of cytogenetics 
and MLPA with the P056 kit. Key exons of TP53, NRAS, 
KRAS, PTPN11, FLT3, and CBL were assessed for 
mutations by denaturing high-performance liquid 
chromatography and Sanger or next-generation 
sequencing as previously described.8,9 Patients were 
further classified according to the UKALL somatic copy 
number alteration classifier into good, intermediate, or 
poor-risk groups,13 and according to IKZF1plus profile 
Figure 1: Schematic showing outcome of patients with B-cell precursor-acute lymphoblastic leukaemia with late bone marrow relapses in the ALLR3 trial as 
per allocated treatment
First complete remission refers to the time from completing front-line therapy. High minimal residual disease defined as ≥10–⁴ cells. Low minimal residual disease 
defined as <10–⁴ cells. SCT=stem-cell transplantation. 
11 with minimal residual disease 
not evaluable and first complete 
remission ≥24 months
82 with low minimal residual 
disease
93 not allocated to SCT 
220 achieved second complete remission 
228 patients treated 
8 did not achieve second complete remission
 5 deaths during induction
 3 induction failures
  
127 allocated to SCT 
1 early treatment-related 
mortality
1 early treatment-related 
mortality
81 completed all three stages of 
chemotherapy before time for 
SCT
11 received SCT
10 second complete 
remission
2 late treatment-related 
mortality
19 relapses
49 second complete remission 
with chemotherapy
10 completed all three stages of 
chemotherapy before time for 
SCT
4 received SCT
1 second complete remission
2 relapses
4 second complete remission 
with chemotherapy
17 with minimal residual disease 
not evaluable and first complete 
remission <24 months
110 with high minimal residual 
disease 
7 did not complete all three 
stages of chemotherapy 
before time for SCT
3 treatment-related 
mortality
4 early relapse
17 completed all three stages of 
chemotherapy before time for 
SCT
4 received chemotherapy
2 second complete remission
1 post-SCT treatment-related 
mortality
1 post-SCT relapse
11 second complete remission
 with SCT
103 completed all three stages of 
chemotherapy before time for 
SCT
11 received chemotherapy
3 second complete 
remission
13 post-SCT treatment-related 
mortality
21 post-SCT relapses
58 second complete remission 
with SCT
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(IKZF1 deletions with concomitant CDKN2A/B, PAX5, 
or PAR1 deletions) as previously described,10 with the 
exception of ERG deletions, which were assumed to be 
either absent or rare in this relapse cohort, given their 
association with good outcomes in patients with acute 
lymphoblastic leukaemia.14,15
Outcomes
In the original study,7 the primary outcome was 
progression-free survival and the secondary outcome was 
overall survival. Progression-free survival was defined as 
the time from relapse, by the date of registration in the 
ALLR3 trial until induction failure, second relapse, 
second tumour or death, or censoring at last contact if no 
events had been observed. Overall survival was defined 
as the time from first relapse to death, censoring at last 
contact if no events had been observed. This long-term 
follow-up analysis was planned once the trial closed, 
although the follow-up period was not specified. The 
primary outcome of the long-term follow-up analysis, 
after closure of randomisation, was defined in the study 
protocol as progression-free survival of patients stratified 
Patients (%) Log-rank analysis Univariate Cox regression analysis
Progression-free 
survival (95% CI)
p value Overall survival 
(95% CI)
p value HR (95% CI) for 
progression-free survival
p value HR (95% CI) for 
overall survival
p value
Total 228 (100%) 60 (54–70) ·· 72 (65–78) ·· ·· ·· ..
Age, years
1–9 118 (52%) 61 (51–70) 0·72 72 (63–80) 0·72 1 .. 1 ..
10–14 77 (34%) 62 (50–72) ·· 72 (60–81) ·· 0·95 (0·59–1·52) 0·84 1·02 (0·58–1·78) 0·95
≥14 33 (14%) 55 (36–71) ·· 70 (50–83) ·· 1·22 (0·69–2·15) 0·50 1·31 (0·67–2·54) 0·43
Sex
Women 102 (45%) 68 (58–77) 0·063 75 (65–83) 0·36 1 .. 1 ..
Men 126 (55%) 55 (45–63) ·· 69 (60–77) ·· 1·50 (0·97–2·30) 0·065 1·27 (0·77–2·09) 0·36
Site
Isolated bone marrow 186 (82%) 62 (54–69) 0·60 75 (67–81) 0·24 1 .. 1 ..
Combined bone marrow* 42 (18%) 54 (37–68) ·· 60 (43–74) ·· 1·15 (0·69–1·93) 0·60 1·41 (0·79–2·51) 0·25
Minimal residual disease at timepoint 1†
<10–⁴ cells 82 (43%) 72 (60–81) 0·0078 87 (77–93) 0·0013 1 .. 1 ..
≥10–⁴ cells 110 (57%) 56 (46–65) ·· 64 (54–73) ·· 1·94 (1·18–3·18) 0·009 2·77 (1·45–5·31) 0·0020
Intended treatment‡
Chemotherapy 93 (42%) 68 (57–77) 0·078 84 (74–90) 0·020 1 .. 1 ..
Stem-cell transplantation 127 (58%) 59 (49–67) ·· 66 (56–74) ·· 1·50 (0·95–2·36) 0·080 1·94 (1·10–3·41) 0·022
Intended and received treatment§
Chemotherapy 76 (42%) 70 (57–79) 0·39 86 (75–92) 0·046 1 .. 1 ..
Stem-cell transplantation 105 (58%) 67 (56–75) ·· 71 (60–79) ·· 1·26 (0·74–2·12) 0·39 1·96 (1·00–3·84) 0·050
Actual treatment¶
Chemotherapy 91 (43%) 64 (53–73) 0·96 83 (73–90) 0·11 1 .. 1 ..
Stem-cell transplantation 120 (57%) 67 (57–75) ·· 72 (63–80) ·· 1·01 (0·64–1·59) 0·96 1·43 (0·82–2·48) 0·21
Genetic abnormalities
Cytogenetic risk||
Standard 132 (60%) 66 (57–74) 0·0006 77 (68–84) 0·0005 0·64 (0·41–1·01) 0·054 0·61 (0·35–1·04) 0·070
Intermediate 69 (32%) 56 (43–67) ·· 69 (56–78) ·· 1 .. 1 ..
High 18 (8%) 30 (11–52) ·· 39 (16–62) ·· 2·09 (1·08–4·06) 0·030 2·35 (1·12–4·94) 0·024
Individual copy number alterations or mutations**
IKZF1 37 (24%) 54 (37–68) 0·13 65 (47–78) 0·058 1·51 (0·88–2·59) 0·14 1·81 (0·97–3·39) 0·062
NR3C1 9 (7%) 42 (11–71) 0·40 63 (24–87) 0·96 1·48 (0·59–3·72) 0·41 1·03 (0·32–3·35) 0·96
PAX5 27 (17%) 65 (43–80) 0·77 77 (57–89) 0·96 0·90 (0·46–1·78) 0·77 1·02 (0·47–2·19) 0·96
IKZF1/PAX5/NR3C1 56 (34%) 49 (35–61) 0·012 63 (49–75) 0·014 1·85 (1·34–3·00) 0·013 2·01 (1·14–3·57) 0·016
NRAS 16 (11%) 38 (15–60) 0·030 52 (24–74) 0·12 2·10 (1·06–4·15) 0·034 1·88 (0·83–4·25) 0·13
IKZF1/PAX5/NR3C1/NRAS 63 (38%) 50 (37–62) 0·010 65 (52–76) 0·032 1·87 (1·15–3·02) 0·011 1·85 (1·04–3·28) 0·035
Progression-free survival and overall survival are shown as 5-year estimates with 95% CI. *Extramedullary sites: CNS (n=25), testes (n=16), skin (n=1). †Measured for those in second complete remission. 
‡Censored at second complete remission. §Censored at time for stem-cell transplantation analysed as intention to treat. ¶Censored at time for stem-cell transplantation analysed as treated. ||Patients with 
unknown cytogenetics excluded. High-risk group includes iAMP21 (n=11), KMT2A (n=4), TCF3-PBX1 (n=1), low hypodiploid (n=1), and haploid (n=1). **Data shown are the presence of each copy number 
alteration or mutation and the comparison is for present versus not present. Full details are provided in the appendix (pp 2–6).
Table 1: Frequency and outcome of patients with late bone marrow relapses, stratified by clinical characteristics, treatment, responses, and genetic features
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by minimal residual disease level. Secondary outcomes 
of the long-term follow-up cohort included progression-
free survival and overall survival within risk groups, by 
treatment given (ie, chemotherapy or stem-cell trans-
plantation) and the proportion of patients with minimal 
residual disease levels available at timepoints 1 and 2.
Treatment-related serious adverse events were reported 
in the report of the original study7 and were not analysed 
in the long-term follow-up.
Statistical analysis
Survival analyses were done with the Kaplan-Meier 
method and differences in progression-free survival and 
overall survival were assessed with the two-tailed log-
rank test. Cumulative incidence of relapse was estimated, 
taking into account death as a competing risk and then 
compared with the Gray test. Other comparisons were 
done with the χ² test, Fisher’s exact test, or Mann-
Whitney U test, as appropriate. Univariate and 
multivariate analyses were done with Cox regression 
models. The prognostic effect of chemotherapy and 
stem-cell trans- plantation was analysed by both intention 
to treat and treatment received, and compared with the 
Mantel-Byar method.15 Most prognostic factors had some 
missing data (appendix pp 2–5). For multivariate analysis, 
missing values were imputed with multiple imputation 
by chained equations.13 60 imputed datasets were created 
with simulated values for missing values from a set of 
imputation models constructed from all of the potential 
prognostic factors and outcome variables (Nelson-Aalen 
estimator for each of progression-free survival and 
overall survival). Distributions of imputed values were 
visually checked for comparability with the observed 
data. Cox regression analysis was done on each imputed 
dataset and the imputation-specific coefficients were 
combined with Rubin’s rules.14 The significance of each 
prognostic factor was assessed with the Wald test statistic. 
Only prognostic factors associated with the outcome 
(p<0·1) in univariate analyses were considered in 
multivariate analyses. The final multivariate model was 
built with progression-free survival and backwards 
selection was done on the pooled coefficients with 
p values less than 0·1 to remove variables. The final 
model was assessed for proportional hazards with 
Schoenfeld residuals,16 assessed by the Harrell’s c-index 
measure of discrimination, and applied to overall survival 
data. The c-index was estimated in each imputed dataset 
and then pooled across imputations with Rubin’s rules. 
Sensitivity analyses were done only in cases with 
complete data about the risk factors in the final model. 
All analyses were done with Intercooled Stata, version 14, 
and R, version 3.4.3.
This trial is registered on the ISRCTN registry, number 
ISRCTN45724312, and on ClinicalTrials.gov, number 
NCT00967057, and is now completed.
Role of the funding source
The funders and sponsors of the study had no role in 
study design, data collection, data analysis, data 
interpretation, writing of the report, or the decision to 
submit the paper for publication. VS, CP, SK, AVM, and 
LH had access to all the raw data. The corresponding 
author had full access to all the data in the study and had 
final responsibility for the decision to submit for 
publication.
Results
Between Feb 2, 2003, and Oct 28, 2013, 228 patients with 
B-cell precursor acute lymphoblastic leukaemia and late 
bone marrow relapses were treated. After a median 
follow-up of 84 months (IQR 48–109), progression-free 
survival was 60% (95% CI 54–70) and overall survival was 
72% (65–78). There were three (1%) induction failures, 
Figure 2: 5-year Kaplan-Meier estimates of (A) progression-free survival and (B) overall survival in patients 
with high and low minimal residual disease
High minimal residual disease defined as ≥10–⁴ cells. Low minimal residual disease defined as <10–⁴ cells.
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five (2%) induction deaths, and 220 (97%) patients 
achieved second complete remission. For the mito- 
xantrone treatment group (n=173), the median age was 
10·1 years (IQR 7·33–12·9) and mean age was 10·5 years 
(SD 3·6); for the idarubicin treatment group (n=55) the 
median age was 9·6 years (6·9–13·2) and mean age was 
10·1 years (3·7). Consistent with the previously published 
randomised analyses,7 5-year progression-free survival 
was significantly higher with mitoxantrone treatment 
than with idarubicin (66% [95% CI 58–73] vs 46% [33–59]; 
p=0·0098), although overall survival did not differ 
significantly between the two groups (75% [67–81] vs 63% 
[49–74]; p=0·10). As reported previously,9 the proportion 
of patients with low minimal residual disease at 
timepoint 1 was similar with both drugs (63 [43%] of 147 
with mitoxantrone vs 19 [41%] of 46 with idarubicin). 
Among patients with late relapses, neither the duration 
of first complete remission nor the time since stopping 
front-line treatment were significantly associated with 
the 5-year outcome (appendix pp 2–5).
Figure 1 shows outcomes after the second complete 
remission. Minimal residual disease at timepoint 1 was 
evaluable in 192 (87%) patients, 82 (43%) of whom had 
low minimal residual disease. Of the 28 patients with 
no minimal residual disease measurements available, 
11 had relapsed 24 months or more after stopping front-
line therapy and were allocated, along with patients who 
had low minimal residual disease, to the no stem-cell 
transplantation group. The remaining 17 patients with 
minimal residual disease measurements, who relapsed 
within 24 months of stopping front-line therapy, together 
with 110 patients with high minimal residual disease, 
were allocated to the stem-cell transplantation group. 
Thus, 93 (42%) patients were allocated to the no stem-cell 
transplantation group and 127 (58%) allocated to stem-
cell transplantation. In the no stem-cell transplantation 
group, two treatment-related deaths were reported before 
completion of phase 3 of treatment. Of the 91 patients 
who completed all three phases of chemotherapy, 
15 (16%) actually received stem-cell transplantation and 
11 remained in second complete remission (with one 
treatment-related death and three relapses after stem-cell 
transplantation). Of the 76 patients who continued 
on chemotherapy as allocated, there were two (2%) 
treatment-related deaths at a late stage in maintenance 
therapy, 21 (28%) second relapses, and 53 (70%) patients 
remained in second complete remission. In the stem-cell 
transplantation group, three treatment-related deaths 
and four second relapses were reported before stem-cell 
transplantation. 15 patients did not undergo trans- 
plantation and instead continued with chemotherapy; 
five (33%) of these patients remained in second complete 
remission. Of the 105 transplanted patients, 22 (21%) 
relapsed again, 14 (13%) died of transplant-related 
complications, and 69 (66%) remained in second 
complete remission.
As stratification to stem-cell transplantation or chemo- 
therapy was guided by minimal residual disease at 
timepoint 1 and duration of first complete remission was 
similar in both groups (appendix p 8), we separately 
examined outcomes of patients in whom minimal 
residual disease at timepoint 1 was measured. 70 patients 
with low-level minimal residual disease allocated to no 
stem-cell transplantation completed the first 12 weeks of 
chemotherapy and continued treatment. There were 
two (3%) treatment-related deaths, 19 (27%) second 
relapses (five late in maintenance and 14 after completing 
therapy), and 49 (70%) patients remained in second 
complete remission at final follow-up. 11 patients with 
low minimal residual disease were transplanted, of 
whom ten remained in second complete remission. 
103 (94%) of 110 patients with high minimal residual 
disease allocated to stem-cell transplantation reached the 
timepoint for stem-cell transplantation. Of the 11 patients 
not transplanted, seven relapsed again, one died, and 
three remained in second complete remission. Of the 
Patients (%) Log-rank analysis Gray’s test Univariate Cox regression analysis 
(Mantel-Byar method)
Competing risk 
regression
Progression-free 
survival (95% CI)
p value Overall 
survival 
(95% CI)
p value Cumulative 
incidence of 
relapse 
p value Progression-free 
survival, hazard 
ratio (95% CI)
Overall survival Subdistribution 
hazard ratio 
High minimal residual disease
Chemotherapy 11 (11%) 31 (11–56) 0·13 54 (28–75) 0·37 50 (16–77) 0·034 1 1 1
Stem-cell transplantation 92 (89%) 54 (34–71) ·· 59 (36–75) ·· 22 (14–31) ·· 0·57 (0·28–1·19), 
p=0·13
0·69 (0·31–1·56), 
p=0·38
0·36 (0·16–0·83), 
p=0·016
Low minimal residual disease
Chemotherapy 70 (86%) 70 (57–79) 0·20 85 (74–92) 0·74 26 (16–38) 0·23 1 1 1
Stem-cell transplantation 11 (14%) 88 (39–98) ·· 100 ·· 13 (5–44) ·· 0·29 (0·04–2·15), 
p=0·23
0·71 (0·09–5·56), 
p=0·74
0·32 (0·04–2·36), 
p=0·27
High minimal residual disease defined as ≥10–⁴ cells. Low minimal residual disease defined as <10–⁴ cells. To compare the prognostic effect of chemotherapy with stem-cell transplantation, the Mantel-Byar 
method was applied in which time starts at the moment of treatment initiation, and all patients begin in the non-transplantation group. Those who receive the transplant enter the transplantation group at 
the time of transplantation and remain there until death, second relapse, or censoring.
Table 2: Cumulative incidence functions for competing events in patients receiving chemotherapy or stem-cell transplantation within the high and low minimal residual disease groups
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92 transplanted patients, 13 (14%) died of transplant-
related complications, 21 (23%) had a second relapse, 
and 58 (63%) remained in second complete remission. 
Survival outcomes at 5 years were significantly higher in 
patients with low minimal residual disease than in those 
with high minimal residual disease (progression-free 
survival 72% [95% CI 60–81] vs 56% [46–65], p=0·0078; 
overall survival 87% [77–93] vs 64 [54–73], p=0·0013; 
table 1, figure 2). Patients allocated to the no 
stem-cell transplantation group had significantly better 
progression-free survival and overall survival than did 
those allocated to the stem-cell transplantation group. 
Although a difference in overall survival was observed 
when patients were censored at second complete 
remission (p=0·010), no differences in outcomes were 
observed in the two groups when analysed on the basis of 
actual treatment received (table 1, appendix p 2).
As minimal residual disease at timepoint 1 was used to 
allocate patients to stem-cell transplantation, we 
examined the effect of stem-cell transplantation versus 
chemotherapy stratified by minimal residual disease at 
timepoint 1 (appendix p 6). For patients with high 
minimal residual disease at timepoint 1, receiving stem-
cell transplantation significantly reduced their relapse 
risk (hazard ratio [HR] 0·36 [95% CI 0·16–0·83], 
competing risk analysis Gray’s test p=0·016) compared 
with chemotherapy alone. By contrast, for patients with 
low minimal residual disease at timepoint 1, no clear 
benefit was seen with stem-cell transplantation and all 
patients had an overall survival greater than 85% at 
5 years (table 2).
We investigated the effect of minimal residual disease 
at timepoint 2 (before stem-cell transplantation) because 
high minimal residual disease before stem-cell 
transplantation has been associated with higher relapse 
rates.16–19 The actual minimal residual disease and 
outcomes after stem-cell transplantation are shown in 
the appendix (pp 6–7). No patients with low minimal 
residual disease at timepoint 1 had high minimal residual 
disease at timepoint 2 and one patient with no minimal 
residual disease result at timepoint 1 was found to 
have high minimal residual disease at timepoint 2. In 
patients who underwent transplantation, progression-
free survival was 68% (95% CI 53–79) and overall survival 
was 77% (62–87) in those with low minimal residual 
disease at timepoint 2, whereas progression-free survival 
was 58% (95% CI 36–75) and overall survival was 
61% (38–77) in those with high minimal residual disease 
at timepoint 2. The differences in outcomes were not 
significant (HR 1·69 [95% CI 0·80–3·61], p=0·18, for 
progression-free survival; and 1·83 [0·78–4·27], p=0·16, 
for overall survival; appendix p 7), possibly reflecting the 
small numbers and the unexpected poor outcome of 
patients with a minimal residual disease level of 0. 
Although the trial recommended only matched-donor 
stem-cell transplantation, other donors were used and 
outcomes within the different donor groups were similar. 
In the six patients for whom the donor source was 
unknown, five had adverse events and one had a follow-
up period of 2 years (appendix pp 2–5). Competing risk 
analyses showed relapse as the most frequent event after 
stem-cell transplantation, although transplant-related 
mortality also influenced outcomes (appendix p 9).
132 (60%) of 228 patients in this follow-up cohort had 
standard-risk cytogenetics (ETV6-RUNX1 and high 
hyperdiploid), and had significantly improved 
progression-free survival and overall survival (table 1, 
appendix p 10).  The distribution of patients by cytogenetic 
risk group did not differ significantly when they were 
Low minimal residual 
disease (n=82)
High minimal residual 
disease (n=110)
p value*
Age, years
Mean (SD) 10·33 (3·16) 10·29 (3·60) ··
Median (IQR) 10·08 (6·58–12·17) 9·33 (7·25–13·08) 0·68
Sex
Women 38 (46%) 48 (44%) 0·71
Men 44 (54%) 62 (56%) ··
Drug
Mitoxantrone 63 (77%) 84 (76%) 0·94
Idarubicin 19 (23%) 26 (24%) ··
Single site
Isolated bone marrow 66 (80%) 91 (83%) 0·59
Bone marrow with CNS 7 (9%) 12 (11%) ··
Bone marrow with testes or skin 9 (11%) 7 (6%) ··
Combined sites
Isolated bone marrow 66 (80%) 91 (83%) 0·69
Combined bone marrow 16 (20%) 19 (17%) ··
Cytogenetic risk
Standard 56 (71%) 59 (57%) 0·12
Intermediate 20 (25%) 36 (35%) ··
High 3 (4%) 9 (9%) ··
UKALL CNA profile 
Good risk 25 (48%) 30 (39%) 0·33
Intermediate or poor risk 27 (52%) 46 (61%) ··
Deletions or mutations
IKZF1 9 (17%) 21 (28%) 0·18
NR3C1 1 (3%) 6 (8%) 0·18
PAX5 7 (13%) 17 (22%) 0·21
IKZF1/PAX5/NR3C1 13 (24%) 33 (41%) 0·039
CDKN2A/B 18 (35%) 25 (33%) 0·91
ETV6 11 (21%) 11 (14%) 0·33
TP53 5 (8%) 6 (7%) 0·74
P2RY8-CRLF2 4 (8%) 6 (8%) 1
NRAS 5 (9%) 7 (10%) 0·92
KRAS 7 (13%) 7 (10%) 0·58
IKZF1/PAX5/NR3C1/NRAS 16 (29%) 36 (44%) 0·060
Patients without minimal residual disease measured at timepoint 1 were excluded. High minimal residual disease 
defined as ≥10–⁴ cells. Low minimal residual disease defined as <10–⁴ cells. CNA=copy number alteration. *p value for χ², 
Fisher’s exact test, or Mann-Whitney U test.
Table 3: Distribution of patients by minimal residual disease level measured at the end of induction 
stratified by clinical characteristics, treatment, and genetic features
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stratified by minimal residual disease risk group (table 3). 
Within the standard-risk cytogenetic group, outcomes of 
ETV6-RUNX1 and high hyperdiploid patients did not 
differ: progression-free survival was 63% (95% CI 48–75) 
versus 68% (55–77) and overall survival was 77% (95% CI 
63–87) versus 77% (65–85). Although patients with high-
risk cytogenetics were rare, their outcome was poor and 
similar to that of patients with early bone marrow 
relapses, as previously reported.8 131 (57%) to 181 (79%) 
patients were screened at relapse for a range of somatic 
copy number alterations and mutations affecting 15 genes 
(appendix pp 3–5). The frequency of some of these 
deletions and mutations varied with the underlying 
cytogenetic risk group and with the likelihood of minimal 
residual disease positivity at the end of induction 
(figure 3). In particular, deletions affecting IKZF1 were 
more prevalent in the intermediate-risk and high-risk 
cytogenetic groups than in the standard risk group. 
Similarly, these patients were more likely to have minimal 
residual disease positivity at end of induction (table 3). 
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Figure 3: Frequency of somatic copy number alterations and mutations according to (A) cytogenetic risk groups and (B) minimal residual disease at 
timepoint 1
High minimal residual disease defined as ≥10–⁴ cells. Low minimal residual disease defined as <10–⁴ cells.
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Patients with deletions in IKZF1, NR3C1, and PAX5 
showed inferior outcomes or a likelihood of minimal 
residual disease positivity at the end of induction, or a 
combination of both, but these findings were not 
significant (table 1, table 3); however, when grouped 
collectively, these outcomes were significant (p=0·014). 
Although mutations in NRAS were relatively rare 
(observed in 16 [11%] of 150 patients), patients with an 
NRAS mutation had significantly worse progression-free 
survival and overall survival (p=0·030; table 1) despite this 
mutation not being strongly associated with minimal 
residual disease at end of induction. Collectively, patients 
with a deletion or mutation in IKZF1, PAX5, NR3C1, or 
NRAS had a progression-free survival of approximately 
50% (95% CI 37–62; table 1).
To ascertain whether these risk factors were independent 
of each other, we did multivariate Cox regression modelling. 
Somatic copy number alterations and mutations were 
considered individually as well as collectively (IKZF1, 
PAX5, or NR3C1; and IKZF1, PAX5, NR3C1, or NRAS). 
Only end-of-induction minimal residual disease and NRAS 
mutations remained significant independent risk factors 
for both progression-free survival and overall survival 
(table 4). The prognostic performance of the final models 
was 68% for progression-free survival and 70% for overall 
survival, as measured by Harrell’s c-index (table 4). Adverse 
genetic features (data not shown) were not observed and 
other risk factors were not associated with relapse after 
stem-cell transplantation (appendix pp 2–6).
HR (95% CI) p value p value 
(joint test)
Imputation model (n=220)
Progression-free survival
Sex
Men vs women 1·60 (1·00–2·56) 0·049 ··
Drug
Idarubicin vs 
mitoxantrone
1·54 (0·96–2·47) 0·072 ··
Minimal residual disease*
High vs low 1·71 (1·05–2·78) 0·031 ··
Cytogenetic risk
Standard vs 
intermediate
0·74 (0·46–1·20) 0·22 0·091
High vs intermediate 1·68 (0·76–3·73) 0·20 ··
NRAS
Mutated vs wild type 2·08 (1·06–4·13) 0·036 ··
Model performance
C-index=0·68 ·· ·· ··
Overall survival
Sex
Men vs women 1·54 (0·88–2·70) 0·14 ··
Drug
Idarubicin vs 
mitoxantrone
1·36 (0·77–2·40) 0·29 ··
Minimal residual disease*
High vs low 2·42 (1·29–4·56) 0·006 ··
Cytogenetic risk
Standard vs 
intermediate
0·77 (0·43–1·38) 0·38 0·084
High vs intermediate 2·04 (0·83–5·02) 0·12 ··
NRAS
Mutated vs wild type 2·27 (1·03–5·02) 0·040 ..
Model performance
C-index=0·70 ·· ·· ··
(Table 4 continues in next column)
HR (95% CI) p value p value 
(joint test)
(Continued from previous column)
Available cases (n=118)
Progression-free survival
Sex
Men vs women 1·68 (0·90–3·13) 0·10 ··
Drug
Idarubicin vs 
mitoxantrone
1·34 (0·72–2·48) 0·359 ··
Minimal residual disease*
High vs low 2·00 (1·05–3·79) 0·034 ··
Cytogenetic risk
Standard vs 
intermediate
0·91 (0·49–1·71) 0·77 0·63
High vs intermediate 1·55 (0·51–4·75) 0·44 ··
NRAS
Mutated vs wild type 1·27 (0·53–3·07) 0·59 ··
Model performance
C-index=0·64 ·· ·· ··
Overall survival
Sex
Men vs women 1·87 (0·86–4·08) 0·11 ··
Drug
Idarubicin vs 
mitoxantrone
1·15 (0·54–2·49) 0·72 ··
Minimal residual disease*
High vs low 2·45 (1·08–5·56) 0·032 ··
Cytogenetic risk
Standard vs 
intermediate
1·03 (0·48–2·24) 0·94 0·70
High vs intermediate 1·75 (0·46–6·67) 0·41 ··
NRAS
Mutated vs wild type 1·70 (0·63–4·57) 0·30 ··
Model performance
C-index=0·65 ·· ·· ··
Patients who did not have successful induction (n=8) were excluded from the 
modelling, as end of induction minimal residual disease was included in imputed 
missing data. *Minimal residual disease was measured at the end of induction. 
High minimal residual disease defined as ≥10–⁴ cells. Low minimal residual disease 
defined as <10–⁴ cells.
Table 4: Final multivariate Cox regression models for progression-free 
survival and overall survival for patients in the ALLR3 trial with late 
bone marrow relapses
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Discussion
The long-term follow-up analyses of the ALLR3 trial 
indicate favourable outcomes in patients with B-cell 
precursor-acute lymphoblastic leukaemia and late bone 
marrow relapses who were risk stratified by minimal 
residual disease at end of induction to not undergo stem-
cell transplantation and to continue chemotherapy. There 
are various caveats to this observation. The median 
follow-up time of this cohort was around 8 years and 
although almost all events occurred within this time, a 
few late relapses are still expected. Information about 
minimal residual disease was not available in 28 (13%) of 
220 patients at timepoint 1, and these patients were 
stratified for stem-cell transplantation according to 
duration of first complete remission. The data suggest 
that time to relapse is not predictive of end-of-induction 
minimal residual disease and patients in this category 
might not have been risk stratified appropriately. 30 (14%) 
of the 211 patients who completed the first three blocks of 
therapy were not treated according to the risk 
stratification. The findings from the ALLR3 trial and the 
ALL REZ BFM 2002 trial3 indicate that in the real-world 
setting around 15% of patients are unable to follow the 
recommended treatment plan stratified by minimal 
residual disease level. We speculate that for patients in 
the low minimal residual disease group, the decision to 
transplant might reflect intolerance to therapy coupled 
with the availability of a matched donor. The results from 
the ALLR3 and ALL REZ BFM 2002 trials suggest that 
although this is a reasonable approach for such patients, 
fractionated total body irradiation is associated with long-
term toxicities. Some patients with high minimal 
residual disease were possibly not transplanted because 
of the unavailability of a matched donor. For transplanted 
patients, pre-stem-cell transplantation minimal residual 
disease with fewer than 10–⁴ cells was associated with the 
best outcomes, although survival after stem-cell trans-
plantation in patients with higher minimal residual 
disease levels at timepoint 2 was also better than 
previously reported.19 The numbers are small in this 
group, and factors such as conditioning, immuno-
suppression, and graft versus host disease, which 
contribute to outcomes after stem-cell transplantation, 
were not analysed.
In patients in whom end-of-induction minimal residual 
disease was assessed, those with fewer than 10–⁴ cells had 
with significantly better outcomes than did those with 
10–⁴ cells or more. Patients with combined and isolated 
late bone marrow relapses had similar survival, and we 
conclude that prophylactic cranial irradiation is not 
necessary in patients with isolated late bone marrow 
relapses. In the ALL REZ BFM 2002 study, similar 
outcomes were observed for patients with minimal 
residual disease of fewer than 10–³ cells with no stem-cell 
transplantation (overall survival 68%) and in those with 
minimal residual disease of 10–³ cells or more with stem-
cell transplantation (overall survival 73%).3 Although 
induction therapies were different in REZ2002 and 
ALLR3, by the time patients reach this stage of disease, 
they have been exposed to multiple modalities of therapy, 
both during front-line and relapse treatment. In this 
study, second relapses occurred in 28% of patients 
allocated to receive chemotherapy only on the basis of 
their end-of-induction minimal residual disease. These 
relapses occurred mostly after stopping therapy or late in 
maintenance and were often rescued with a stem-cell 
transplantation in third complete remission. This 
implies that these recurrent clones continue to be 
chemosensitive. Thus, a minimal residual disease level 
of fewer than 10–⁴ cells at end of induction appears to be 
more sensitive than that of fewer than 10–³ cells in 
identifying patients with late bone marrow relapses who 
do not require stem-cell transplantation. Newer, more 
sensitive minimal residual disease assays20 might predict 
more clearly which patients within the low minimal 
residual disease group are likely to remain in second 
complete remission and not have a second relapse, but 
this hypothesis needs to be prospectively investigated. 
Patients with a minimal residual disease of 10–⁴ cells or 
more at timepoint 1 benefited from stem-cell 
transplantation. This observation suggests that high-risk 
disease can be defined as a minimal residual disease of 
10–⁴ cells or more. Similar to findings of the ALLREZ 
BFM 2002 study, matched donor stem-cell transplantation 
appeared to be associated with better outcomes, although 
in both studies the choice of donor was not significant. 
Second relapse rates were high in patients with high-
level minimal residual disease who were not transplanted. 
As a result of advances in transplantation, outcomes for 
patients with late bone marrow relapses who undergo 
stem-cell transplantation with a mismatched donor are 
similar to those of patients who undergo stem-cell 
transplantation with a matched donor.21 This indicates 
that in patients with high minimal residual disease who 
have late bone marrow relapses, stem-cell transplantation 
with any donor should be the preferred option.
Latency of recurrence (duration of first complete 
remission) was not predictive for minimal residual 
disease, and differences in minimal residual disease 
kinetics are thought to reflect the different underlying 
biology of acute lymphoblastic leukaemia subtypes, and 
not exclusively drug sensitivity.22 In the high minimal 
residual disease group, four patients relapsed before 
undergoing stem-cell transplantation, one had high-risk 
cytogenetics, and the other had an IKZF1plus profile, 
supporting the contention that minimal residual disease 
reflects the biology of acute lymphoblastic leukaemia. 
TP53 deletions and mutations did not influence 
outcomes in this cohort,8,9 but only one patient harboured 
a point mutation and the other 11 TP53 alterations were 
heterozygous deletions. Univariate analyses showed a 
deleterious effect of IKZF1, PAX5, or NR3C1 mutations 
on outcome and these somatic copy number alterations 
were more frequent in patients with high minimal 
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residual disease. IKZF1, NR3C1, and PAX5 regulate 
glucose metabolism in B-cell precursor lymphoblasts and 
haploinsufficiency leads to increased glucose metabolism 
and promotes resistance to glucocorticoids,17 establishing a 
plausible biological mechanism for residual disease after 
therapy. In murine models, targeting the metabolic 
processes regulated by these genes restored sensitivity to 
glucocorticoids, indicating potential targeted therapeutic 
alternatives.23 The results of this study show that stem-
cell transplantation offers reasonable outcomes for 
patients with high minimal residual disease and patients 
who relapsed after stem-cell transplantation did not have 
these somatic copy number alterations. Both recurrence 
and mortality after transplantation contributed to the 
worse outcomes in transplanted patients, and no 
predictive variables were identified for relapses after 
stem-cell transplantation in this study. Immune therapies 
target the expression of antigens on the surface of B-cell 
precursor acute lymphoblastic leukaemia, and reduce the 
minimal residual disease burden before trans-
plantation.24–28 These immune therapies could decrease 
recurrences after stem-cell transplantation in patients 
with high minimal residual disease at end of induction 
and might even serve as an alternative to stem-cell 
transplantation in the future. The frequency of the NRAS 
mutations was 11% overall but 19% among high 
hyperdiploid patients. Consistent with previous analysis 
of the entire ALLR3 cohort,8 NRAS mutations were 
associated with an inferior outcome in patients with late 
bone marrow relapses. RAS pathway mutations confer 
sensitivity to MEK inhibition,29 and a phase 1/2 trial is 
currently assessing selumetinib in combination with 
dexamethasone in treatment of patients with multiply 
relapsed childhood acute lymphoblastic leukaemia with 
RAS mutations.30
Overall, the long-term results of the ALLR3 clinical trial 
indicate that patients with B-cell precursor-acute 
lymphoblastic leukaemia who have late bone marrow 
relapses with end of induction minimal residual disease 
of fewer than 10–⁴ cells have satisfactory outcomes with 
available therapeutic modalities. Patients who have a 
higher minimal residual disease at end of induction and 
persistent minimal residual disease before stem-cell 
transplantation might benefit from enrolment into trials 
exploring experimental therapies.
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